Search clinical trials for: Herpes simplex candidate vaccine

Total 12365 results

Wuhan BravoVax Co., Ltd.
Shanghai BravoBio Co., Ltd.

Not yet recruiting

Phase I Clinical Trial of a Candidate Herpes Zoster Vaccine

Herpes Zoster
ModernaTX, Inc.

Active, not recruiting

A Study of mRNA-1608, a Herpes Simplex Virus -2 (HSV-2) Therapeutic Candidate Vaccine, in Healthy Adults 18 to 55 Years of Age With Recurrent HSV-2 Genital Herpes

Genital Herpes

United States
GlaxoSmithKline

Completed

Study to Evaluate the Impact of Reactogenicity on Quality of Life (QoL), After Administration of GlaxoSmithKline (GSK) Biologicals' Candidate Herpes Zoster Subunit (HZ/su) Vaccine (GSK1437173A) in Adults ≥ 50 Years of Age

Herpes Zoster

United States
GlaxoSmithKline

Completed

HerpeVac Trial for Young Women

Herpes Simplex Infection

United States, Canada
GlaxoSmithKline

Completed

Evaluation of Safety of Candidate gD Vaccine, With or Without MPL in Healthy Herpes Simplex Virus-positive Adults

Herpes Simplex
GlaxoSmithKline

Completed

Safety of a Herpes Simplex Candidate Vaccine (gD2t) With MPL and Its Efficacy to Prevent Genital Herpes Disease

Herpes Simplex
GlaxoSmithKline

Completed

Humoral and Cellular Immune Response of Herpes Simplex (gD) Candidate Vaccines From 2 Different Cell Lines

Prophylaxis Herpes Simplex

Belgium
GlaxoSmithKline

Completed

Safety Evaluation of Herpes Simplex Candidate Vaccine (gD2t) With Adjuvant in HSV Seropositive / Seronegative Subjects

Prophylaxis for Herpes Simplex

Austria, Germany, Belgium, United States, Australia, Canada, Denmark, France, Puerto Rico, South Africa, Spain, Switzerland
GlaxoSmithKline

Completed

Evaluation of Immunogenicity, Reactogenicity and Safety of Herpes Simplex (gD) Candidate Vaccine With/Without Adjuvant

Prophylaxis Herpes Simplex

Belgium
Shenzhen Shenxin Biotechnology Co., Ltd

Not yet recruiting

A Study to Describe the Safety, Reactogenicity, and Immunogenicity of Herpes Zoster IN001 mRNA Vaccine (IN001) in Healthy Participants

Herpes Zoster
Fondazione Policlinico Universitario Agostino Gemelli...

Recruiting

Multidisciplinary Hospital-Territory Vaccine Center: a Model for Achieving the Herpes Zoster Vaccine Coverage (CeVOT-Her-Zo)

Herpes Zoster

Italy
Leciel Bono

Recruiting

Hand Sanitizer Use for Herpes Simplex Virus-1

HSV-1 | Herpes Simplex Labialis | Virus | Herpes Simplex 1

United States
Beijing Luzhu Biotechnology Co., Ltd.

Recruiting

A Phase Ⅲ Clinical Study to Evaluate Protective Efficacy and Safety of a Recombinant Herpes Zoster Vaccine

Herpes Zoster | Vaccine-Preventable Diseases

China
National Institute of Allergy and Infectious Diseases...

Recruiting

Cytomegalovirus (CMV) Vaccine in Orthotopic Liver Transplant Candidates (COLT)

Liver Transplant

United States
Global Research Institute
Rational Vaccines Inc

Recruiting

A 48 Week Observational Study of the Frequency of Symptomatic Herpes Virus I and II in HIV Infected Subjects (HSVHIV)

HIV Disease | Herpes Simplex 2 | Herpes Simplex 1

United States
GlaxoSmithKline
Harvard Pilgrim Health Care Institute

Not yet recruiting

Safety of Herpes Zoster Subunit (HZ/su) Vaccine During Pregnancy in Adult Women With Immunocompromised Conditions

Herpes Zoster
Beijing Luzhu Biotechnology Co., Ltd.

Recruiting

A Study to Evaluate Safety and Tolerability of a Recombinant Herpes Zoster Vaccine

Herpes Zoster | Vaccine-Preventable Diseases

United States
Pfizer

Recruiting

A Study to Learn About a Modified RNA Vaccine Against Shingles in Healthy Adults

Shingles | Human | Herpes Zoster Infection

United States
BioNTech SE

Recruiting

A Clinical Trial in Healthy Volunteers to Study the Safety, Tolerability, and Immune Responses After Vaccination With an Investigational Vaccine Designed to Prevent Genital Herpes Lesions

Genital Herpes Simplex Type 2

United States
GlaxoSmithKline

Recruiting

A Study to Test GlaxoSmithKline's (GSK) Candidate Vaccine-GSK1437173A for Prevention of Shingles in Children With Kidney Transplant

Herpes Zoster

Italy, Spain, United Kingdom, France
National Institute of Allergy and Infectious Diseases...
Sanofi Pasteur, a Sanofi Company

Completed

Study of the Safety of a Particular Herpes Vaccine in Adults With or Without Herpes Infection

Healthy Volunteers

United States
GlaxoSmithKline

Completed

Study to Evaluate Immunogenicity and Safety of GSK Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine at 9 and 10 Years After Vaccine Administration and Assessment of Re-vaccination With 2 Additional Doses at 10 Years After Initial Vaccination, in Healthy Subjects Aged 60 Years of Age(YOA) and Older

Herpes Zoster

Germany, Czechia, Sweden
GlaxoSmithKline

Completed

A Study on the Immune Response and Safety of a Vaccine Against Herpes Zoster in Adults Aged 50 Years and Older in India

Herpes Zoster

India
ModernaTX, Inc.

Withdrawn

A Study of mRNA-1647 Cytomegalovirus Vaccine in Liver Transplant Candidates and Recipients

Cytomegalovirus Infection

United States
MAXVAX Biotechnology Limited Liability Company
Henan Center for Disease Control and Prevention

Active, not recruiting

Safety and Immunogenicity of Recombinant Herpes Zoster Vaccine (CHO Cells) in Healthy Subjects Aged 18 Years and Above

Herpes Zoster

China
GlaxoSmithKline

Completed

A Long-term Follow-up Study (ZOE-LTFU) of Two Studies 110390 (ZOSTER-006) and 113077 (ZOSTER-022) to Assess the Efficacy, Safety, and Immunogenicity Persistence of GSK Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine and Assessment of 1 or 2 Additional Doses in Two Subgroups of Older Adults

Herpes Zoster

United States, Australia, Spain, Finland, Germany, Japan, Taiwan, Sweden, Korea, Republic of, Brazil, Mexico, Canada, Italy, France, Czechia, Estonia, Hong Kong, United Kingdom
GlaxoSmithKline

Active, not recruiting

A Study to Evaluate the Safety and Immunogenicity of GlaxoSmithKline's Herpes Zoster Subunit Vaccine (HZ/su) When Given on a Two-dose Schedule to Adults at Least 50 Years of Age (YOA) Who Had Prior Episode of Shingles

Herpes Zoster

Spain, Panama, Mexico, Russian Federation, Finland, Estonia, Hong Kong, United Kingdom
ModernaTX, Inc.

Active, not recruiting

A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Adults

Epstein-Barr Virus Infection

United States
University of Wisconsin, Madison
Boston Medical Center

Active, not recruiting

Immunogenicity of Herpes Zoster Subunit Vaccine in Inflammatory Bowel Disease Patients Treated With Vedolizumab

Inflammatory Bowel Diseases | Crohn Disease | Ulcerative Colitis | Herpes Zoster

United States
GlaxoSmithKline

Active, not recruiting

A Study on the Long-term Efficacy, Safety and Persistence of Immune Response of a Vaccine Against Herpes Zoster in Older Adults

Herpes Zoster

United States, Australia, Finland, Germany, Japan, Taiwan, Sweden, Spain, Korea, Republic of, Brazil, Mexico, Italy, Canada, Czechia, Estonia, France, Hong Kong, United Kingdom
GlaxoSmithKline

Active, not recruiting

A Study to Test GlaxoSmithKline's (GSK) Herpes Zoster (HZ) Subunit Vaccine's Long-term Immune Response in Previously Vaccinated Kidney Transplant Adults and Then to Test if 2 Additional Doses of the Vaccine Are Safe and Able to Generate an Immune Response

Herpes Zoster

Spain, Canada, Belgium, Finland, Korea, Republic of, Panama, Taiwan
ModernaTX, Inc.

Active, not recruiting

A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 12- to 30-Year-Old Healthy Adolescents and Adults

Epstein-Barr Virus Infection

United States
Immorna Biotherapeutics, Inc.
ICON plc

Active, not recruiting

A First-in-Human Study to Evaluate JCXH-105, an srRNA-based Herpes Zoster Vaccine (JCXH-105)

Infectious Disease | Shingles | Herpes Zoster (HZ)

United States
MAXVAX Biotechnology Limited Liability Company
Henan Center for Disease Control and Prevention

Active, not recruiting

Immunogenicity and Safety of Recombinant Herpes Zoster Vaccine (CHO Cells) in Healthy Subjects Aged 30 Years and Above

Herpes Zoster

China
Curevo Inc
Green Cross Corporation; Mogam Biotechnology Research Institute

Active, not recruiting

Safety and Immunogenicity of CRV-101 Vaccine for the Prevention of Herpes Zoster in Adults Aged 50 Years and Older

Herpes Zoster | Shingles

United States
ModernaTX, Inc.

Active, not recruiting

A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1468 in Healthy Adults ≥50 Years of Age

Herpes Zoster

United States, Puerto Rico
Radboud University Medical Center
GlaxoSmithKline

Completed

Age Differences in Influenza and Herpes Zoster Vaccine Responses (INFLUENZA-SHINGRIX)

Influenza | Herpes Zoster

Netherlands
Rational Vaccines Inc

Completed

A Study of the Characteristics of Patients Diagnosed With Recurrent Symptomatic Genital Herpetic Disease

Patient Engagement | Genital Herpes

United Kingdom
Dynavax Technologies Corporation

Completed

Trial to Evaluate the Safety, Tolerability, and Immunogenicity of an Investigational Herpes Zoster Vaccine (Z-1018) Compared to Shingrix® in Healthy Adult Volunteers

Herpes Zoster | Vaccine-Preventable Diseases | Shingles

Australia
Sanofi Pasteur, a Sanofi Company
Immune Design

Terminated

Safety and Efficacy of 4 Investigational HSV 2 Vaccines in Adults With Recurrent Genital Herpes Caused by HSV 2 (HSV15)

Genital Herpes

United States
GlaxoSmithKline

Completed

Immunogenicity and Safety Study of GSK Biologicals' Herpes Zoster Vaccine GSK1437173A When Co-administered With Prevenar13 in Adults Aged 50 Years and Older

Herpes Zoster

United States, Germany, Estonia, Canada
Chimerix

Completed

Study to Assess Brincidofovir Treatment of Serious Diseases or Conditions Caused by Double-stranded DNA Viruses

Double-stranded DNA Virus

United States
Agenus Inc.

Completed

Biological Efficacy Study of HerpV Vaccine With QS-21 to Treat Participants With Recurrent Genital Herpes

Herpes Simplex Type 2

United States
GlaxoSmithKline

Terminated

A Study on the Reactogenicity, Safety and Immune Response of a Vaccine Against Herpes Simplex Virus (HSV)-2 in Healthy Participants Aged 18-40 Years

Herpes Simplex

United States
GlaxoSmithKline

Completed

Study to Evaluate Immunogenicity and Safety Study of GSK Biologicals' Herpes Zoster (HZ) Vaccine GSK1437173A When Co-administered With Pneumovax 23™ in Adults Aged 50 Years and Older

Herpes Zoster | Herpes Zoster Vaccine

United States, Estonia, Canada
GlaxoSmithKline

Completed

Consistency, Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster (HZ) Vaccine GSK1437173A in Adults ≥ 50 Years of Age

Herpes Zoster | Herpes Zoster Vaccine

United States, Canada, Belgium
GlaxoSmithKline

Completed

Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster (HZ/su) Vaccine in Adults With Solid Tumours Receiving Chemotherapy

Herpes Zoster | Herpes Zoster Vaccine

Canada, Spain, Korea, Republic of, United Kingdom, France, Czechia
Jiangsu Province Centers for Disease Control and...

Completed

Efficacy Trial of a Vaccine to Prevent Herpes Zoster in Adults Over 40 Years of Age

Herpes Zoster

China
GlaxoSmithKline

Completed

Cross-vaccination Study of GSK Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine (GSK 1437173A) in Subjects Who Previously Received Placebo in ZOSTER-006 (NCT01165177) and ZOSTER-022 (NCT01165229) Studies.

Herpes Zoster

United States, Australia, Germany, Spain, Finland, Japan, Taiwan, Sweden, Korea, Republic of, Hong Kong, Mexico, Canada, Italy, France, Brazil, Estonia, United Kingdom, Czechia
GlaxoSmithKline

Completed

Study to Evaluate Efficacy, Safety and Immunogenicity of GSK Biologicals' Herpes Zoster (HZ) Vaccine GSK1437173A in Adults Aged 50 Years and Older

Herpes Zoster

United States, Australia, Spain, Finland, Germany, Japan, Taiwan, Canada, Sweden, Korea, Republic of, Czechia, Hong Kong, Mexico, Italy, Brazil, Estonia, France, United Kingdom

3

Subscribe